I didn't have much of a weekend. I was putting out swine flu fires via work emails and dealing with a really bad allergy attack. Plus, it kinda gets cut short by having to go to bed so early (6 o'clock) in order to anchor "Worldwide Exchange" at 4 a.m. ET.
Stocks ended higher Tuesday as investors were encouraged by comments from Treasury Secretary Tim Geithner that most banks are well capitalized.
Stocks turned mixed Tuesday as another wave of disappointing earnings news weighed on the market but tech stocks shined bright.
US stock index futures turned lower ahead of the open Tuesday after key corporate earnings sounded a note of caution for investors.
In this Web Extra, the traders game Coca-Cola, Merck, Capital One and a slew of other companies about to report earnings.
CNBC’s Mike Huckman is keeping a close eye on Big Pharma earnings. And he suggests you do the same - because he's spotted a devil the details.
Next week you could nearly drown in data, considering the flood of earnings reports that are coming. But don’t panic, our traders will keep you afloat.
Stocks closed higher despite some selling in the final half hour of trading, giving the market its sixth straight weekly gain and its longest weekly winning streak since 2007.
With stocks rallying for 5 weeks in a row now, dividend yields are falling back to Earth. The average dividend yield of the Dow 30 has fallen over 25% since the rally began in early March. See how the 30 companies in the Dow compare.
Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.
Stocks fell Monday amid doubts over the health of the banking industry and the apparent collapse of a major deal in the technology sector.
Breakthrough diabetes treatments may be on the horizon. What companies stand to win?
Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.
Stocks capped a relatively good week with a thud Friday as investors locked in profits.
Stocks ended a strong two-week run with a thud Friday as financial stocks took a beating and weakness seeped into other sectors.
The Dow slid on Friday after the Federal Reserve's plan to rekindle consumer and small business lending fell short of expectations...
Stocks were mixed Friday after a strong two-week run as financial stocks continued to struggle as some investors locked in profits. Still, Wall Street could close with its first string of consecutive positive weeks in nearly a year.
The Dow fell on Thursday largely due to concerns that the Federal Reserve's latest efforts to battle the recession are too costly and untested...
US Markets recorded their best week since November, riding four consecutive days of gains, making traders question whether we have found the bottom or if this is merely a bear bounce.
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.